yttrium radioisotopes has been researched along with Lymphoma, Mantle-Cell in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dlugosz-Danecka, M; Giza, A; Gruszka, AM; Hubalewska-Dydejczyk, A; Jakobczyk, M; Jurczak, W; Kisiel, E; Knopińska-Posłuszny, W; Krawczyk, K; Skotnicki, A; Sowa Staszczak, A; Szostek, M; Szymczyk, M; Wróbel, T; Zimowska-Curylo, D; Zinzani, PL | 1 |
| Bergmann, L; Dreyling, M; Ferrero, S; Finke, J; Forstpointner, R; Ghione, P; Hiddemann, W; Keller, U; Passera, R; Pastore, A; Pezzutto, A; Scholz, CW; Trümper, L; Unterhalt, M; Weigert, O | 1 |
| Boulahdour, H; Daguindau, E; Deconinck, E; Helias, P; Philippe, L; Puyraveau, M | 1 |
| Leahy, MF; Turner, JH | 1 |
| Ansell, SM; Habermann, TM; Ristow, KM; Wiseman, GA; Witzig, TE | 1 |
| Micallef, IN | 1 |
| Coleman, M; Furman, RR; Leonard, JP; Ruan, J | 1 |
| Blau, IW; Fietz, T; Gentilini, C; Glass, B; Marinets, O; Muessig, A; Munz, DL; Rieger, K; Sandrock, D; Thiel, E; Uharek, L | 1 |
| Tobinai, K | 1 |
| Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O | 1 |
| Falk, P; Forman, SJ; Fung, HC; Krishnan, A; Molina, A; Nademanee, A; Palmer, JM; Raubitschek, AA; Rodriguez, R; Spielberger, RT; Yamauchi, D | 1 |
2 review(s) available for yttrium radioisotopes and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Stem Cell Transplantation; Survival Analysis; Yttrium Radioisotopes | 2004 |
New developments in immunotherapy for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Humans; Immunotherapy; Interleukin-2; Lymphoma; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2005 |
5 trial(s) available for yttrium radioisotopes and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Consolidation with
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Poland; Prognosis; Prospective Studies; Radioimmunotherapy; Survival Rate; Yttrium Radioisotopes | 2019 |
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Radioimmunotherapy; Survival Rate; Yttrium Radioisotopes | 2016 |
Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Clinical Trials, Phase II as Topic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Radioimmunotherapy; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2011 |
4. Antibody therapy for malignant lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2007 |
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Radioimmunotherapy; Stem Cell Transplantation; Treatment Outcome; Yttrium Radioisotopes | 2008 |
4 other study(ies) available for yttrium radioisotopes and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Follow-Up Studies; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Radioimmunotherapy; Retrospective Studies; Salvage Therapy; Treatment Outcome; Yttrium Radioisotopes | 2002 |
Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents; Cyclophosphamide; Disease Progression; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Radioimmunotherapy; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2006 |
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes | 2007 |